Updated PegIntron Label Psychiatric Warning

Package information for Intron-A conventional interferon and PegIntron pegylated interferon were updated with a warning that people with psychiatric and substance use disorders may experience worse symptoms.

Telaprevir (Incivek) Patient Assistance Program

Vertex Pharmaceuticals has started programs to help people with hepatitis C access its recently approved HCV drug telaprevir.

BI201335 Shows Potent Activity against HCV

HCV protease inhibitor BI201335 plus pegylated interferon/ribavirin was well-tolerated and demonstrated good activity in treatment-naive and -experienced genotype 1 chronic hepatitis C patients.

Boceprevir (Victrelis) Patient Assistance Program

Merck has announced programs to help hepatitis C patients obtain its newly approved HCV protease inhibitor boceprevir.

PSI-7977 + BMS-790052 Trial for Hepatitis C

Pharmasset announced the start of a Phase 2a study of an all-oral antiviral regimen of HCV polymerase inhibitor PSI-7977 plus NS5A replication complex inhibitor BMS-790052.

Telaprevir (Incivek) Approved for Hepatitis C

Caffeine and Liver Disease in People with Hepatitis C

Regularly consuming larger amounts of caffeine has a significant beneficial effect on liver inflammation, but not fibrosis, according to biopsy results from people with chronic hepatitis C.

FDA OKs New Abbott HCV Test

Abbott last week announced that the FDA approved a new PCR blood test for hepatitis C virus (HCV) with a 12 IU/mL limit of detection and quantification.